> ## Content Index
> Fetch the complete content index at: https://acentricresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Diamond (NV-centre) quantum sensing for biology and diagnostics: Junction Brief – November 2026
- URL: https://acentricresearch.com/research/diamond-quantum-sensing-biology-brief-2026-11/
- Published: 2026-11-21T09:21:41.000Z
- Updated: 2026-11-21T09:44:28.000Z
- Author: Kevin Meyer
- Tags: biotechnology-quantum, junction-brief

> Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in [Biotechnology × Quantum in the Landscape Report](https://acentricresearch.com/research/landscape-2026-11/#biotechnology-quantum).

### Overview

Diamond can contain a defect in which a nitrogen atom sits next to a missing carbon atom, called a nitrogen-vacancy (NV) centre (a general definition; the review abstract names the NV centre as the best-known such defect). \[1\] The 2014 review describes such crystal defects, most prominently the NV centre, as able to detect magnetic and electric fields through their quantum spin state. \[1\] That lets a tiny crystal act as a sensor, in principle for ion concentrations, membrane voltages and single-cell measurements. \[1\]\[2\] The 2014 review adds that diamond is very stable and that nanocrystals with these defects can serve as fluorescent biomarkers of unlimited photostability and low cytotoxicity (review abstract). \[1\] The other quantum magnetic sensor used in health care, the optically pumped magnetometer, is covered in the [Junction Brief on brain and heart imaging](https://acentricresearch.com/research/quantum-magnetometry-brain-heart-brief-2026-11/).

What stands out is how early this is for medicine. The sources opened describe laboratory methods and start-up plans, and no product used on patients in the sources opened. The dated sources opened run from 2014 to 2025; the reviews are from 2014 and 2023 and the one company-related source, a university news release relaying a start-up's statements, is from March 2025; and later developments were not searched.

### Current state

**What the technology does.** A 2014 review of NV centres, whose abstract was read, describes sensing of magnetic and electric fields at the nanoscale and applications ranging from ion concentrations and membrane potentials to nanoscale thermometry and single-spin nuclear magnetic resonance. \[1\] A 2023 review of quantum sensors for biomedical applications, also read as an abstract, names NV centres in diamond as one of two promising platforms, along with optically pumped atomic magnetometers, and says that start-ups are increasing and that it is often difficult to evaluate the potential impact. \[2\]

**What the review literature says.** The 2023 review presents four case studies, ranging from brain imaging to single-cell spectroscopy, to show the breadth of biomedical uses of the two sensing platforms, and discusses their path towards commercialization (abstract read; the full text was not read, so which of those uses rely on diamond is not stated here). \[2\]

**Who is working on it.** Deteqt, a University of Sydney Nano Institute spinout, says it is developing diamond-on-silicon quantum magnetometers made with standard semiconductor processes. In March 2025 the University of Sydney reported that Deteqt secured three-quarters of a million dollars of pre-seed funding from two venture investors. \[3\] The company's funded applications, as the university lists them, include navigation without GPS for defence (a $3 million contract with the Australian Defence Force), subterranean imaging for mining, and portable magnetic resonance imaging; for the last, it says it is collaborating with a US partner, OneScan, to assess the potential. \[3\] Medical imaging is one of three stated markets, and the release names no health-care customer or clinical study. The company's own site was not read.

**What was not found.** The sources opened describe no biological deployment and no clinical study; no FDA, ClinicalTrials.gov or literature search for NV-centre products was run for this Brief, so absence elsewhere is not shown.

The 2023 review abstract frames the question of potential impact as open, and the NIH prize challenge for quantum sensing, discussed below, states that use of these technologies in biomedical fields remains narrow. \[2\]\[4\] Deteqt's release says current sensor technologies in mining, health and navigation have hit fundamental limits; this is a company claim, with no evidence for the health case in the release. \[3\]

**How far it has come.** Laboratory methods exist and are reviewed in the literature; one start-up reports an early partnership to assess portable imaging. \[1\]\[2\]\[3\]

### Opportunities

NIH's Quantum Sensing Technology Challenge has a total purse of $1.6 million across two stages; NCATS reports that Stage 1 winning teams will receive $20,000 for their proposals and be invited to Stage 2\. It lists quantum sensing for early detection and diagnostics among three areas of interest, and says atomic-scale sensors offer noninvasive detection of ultra-weak biological signals in the body, work in very small sample volumes, and image without photodamage or photobleaching. \[4\] The challenge is not specific to diamond; the page does not name the winning teams' technologies in the text read. The Deteqt release argues that building sensors on silicon chips could make them low-cost and manufacturable at volume (company claim). \[3\]

### Challenges

- **Physics and engineering.** NCATS says real-world use of quantum sensing in biomedicine requires further optimization, testing and validation. \[4\] The Deteqt release makes no health-specific performance claim, and the 2023 review abstract says it is often difficult to evaluate the potential impact of these techniques in biomedicine. \[3\]\[2\]
- **Regulation.** No regulatory pathway or filing was found for NV-centre medical products; none of the sources opened discusses one. No FDA search was run for this Brief; the one FDA record in this pair is for a heart-imaging system, covered in the [sibling Brief](https://acentricresearch.com/research/quantum-magnetometry-brain-heart-brief-2026-11/). \[5\]\[6\]
- **Capital and scale-up.** The one disclosed round found is a pre-seed of about three-quarters of a million dollars, and its first funded work is in defence and mining. \[3\]

### Data sources

- **NIH RePORTER**, for grants on quantum sensing in biology. \[7\]
- **Europe PMC**, for the research literature on NV centres. \[8\]
- **FDA device databases**, for any future clearance. \[6\]
- **Company websites and funding announcements**, as company claims.
- No registry for this niche was found.

### Changelog

- 2026-11-18: First published.

### Sources

1. Romana Schirhagl and others, "Nitrogen-vacancy centers in diamond: nanoscale sensors for physics and biology", Annual Review of Physical Chemistry, 2014, abstract (Europe PMC record, PMID 24274702; the full text was not read). [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT%5FID:24274702%20AND%20SRC:MED&format=json&resultType=core&ref=acentricresearch.com) (accessed 2026-11-18)
2. Nabeel Aslam and others, "Quantum sensors for biomedical applications", Nature Reviews Physics, 2023, abstract (Europe PMC record, PMID 36776813; the full text was not read). [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT%5FID:36776813%20AND%20SRC:MED&format=json&resultType=core&ref=acentricresearch.com) (accessed 2026-11-18)
3. University of Sydney, "Sydney spinout Deteqt secures backing for diamond-on-silicon sensing tech", 2025-03-31 (university news release relaying company statements). [sydney.edu.au](https://www.sydney.edu.au/news-opinion/news/2025/03/31/sydney-spinout-deteqt-secures-backing-for-diamond-on-silicon-sen.html?ref=acentricresearch.com) (accessed 2026-11-18)
4. National Center for Advancing Translational Sciences, "Quantum Research Activities" (agency page). [ncats.nih.gov](https://ncats.nih.gov/research/research-activities/quantum?ref=acentricresearch.com)(accessed 2026-11-18)
5. openFDA 510(k) database, record K182571, "CardioFlux with Faraday Analytical Cloud", Genetesis, Inc., decision date 2019-03-15, "Substantially Equivalent" (agency data, queried through the API; the device-name searches "magnetoencephalograph\*" and "MEG" returned no optically pumped magnetometer system, which is not proof of absence). [api.fda.gov](https://api.fda.gov/device/510k.json?search=device%5Fname:cardioflux&ref=acentricresearch.com) (accessed 2026-11-18)
6. FDA 510(k), De Novo and PMA databases. [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ref=acentricresearch.com) (listed as a data source; the 510(k) record cited was read through openFDA)
7. NIH RePORTER, project search. [reporter.nih.gov](https://reporter.nih.gov/?ref=acentricresearch.com) (listed as a data source, not opened for this Brief)
8. Europe PMC REST API. [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22quantum%20sensing%22&format=json&ref=acentricresearch.com) (listed as a data source; review abstracts were read through it for other claims in this Brief, 2026-11-18; not searched for this Junction)